Other objectives are : to assess the incidence of treated biopsy-proven acute rejection , graft loss , or death ; the incidences of components of the composite efficacy endpoint ; renal function via estimated glomerular filtration rate using various formulae ( MDRD-4 , Nankivell , Cockcroft-Gault , chronic kidney disease epidemiology collaboration and Hoek formulae ) ; the incidence of proteinuria ; the incidence of adverse events and serious adverse events ; the incidence and severity of cytomegalovirus and HCV infections and HCV-related fibrosis .